Project Grant R21NS142775
Award Date
6/3/25
Completion Date
5/31/27
Dollars Obligated
$388K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Reno, NV 89557, USA
Similar Awards
This Project Grant award of $532,381.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key objectives are to determine the gain-of-function effects of KIF5ADE27 in...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,499,212 Project Grant (CFDA 93.853) to Aquinnah Pharmaceuticals, Inc. to develop a novel oral brain-penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture, conduct IND-enabling studies, and hold a Pre-IND meeting with the FDA for a new drug candidate designed to slow and potentially reverse the progression of ALS by reducing the accumulation of insoluble, aggregated TDP-43...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to investigate the effects of re-expressing embryonic motor neuron selector transcription factors ISL1 and LHX3 in postnatal motor neurons in mouse models of amyotrophic lateral sclerosis (ALS) and in induced pluripotent stem cell-derived ALS motor...
The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, awarded Cedars-Sinai Medical Center a $227,205 project grant. The grant funds a 5-year research project to (1) use advanced MRI techniques to identify pathological markers associated with upper motor neuron degeneration in the motor cortex of amyotrophic lateral sclerosis (ALS) patients, and (2)...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $374,349 to the University of North Carolina at Chapel Hill to develop and optimize a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research aims to establish a mouse model that accurately recapitulates the human disease...
This $121,554 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of RNA processing misregulation by the KIF5A gene in amyotrophic lateral sclerosis (ALS). The research aims to: (1) examine the impact of ALS-related KIF5A mutations on the proteotoxic pathway, (2) explore KIF5A interactions with other ALS-associated...
This $460,625 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology related to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award, provided to the University of Massachusetts Medical School, will utilize mouse models and...
This $2,307,075 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports an ambitious research program at The Leland Stanford Junior University. The funded research aims to define novel mechanisms underlying human neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease, and...
This Project Grant award of $558,182 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The primary objectives are to: 1) compare neurofilament species in ALS and control biofluids to identify ALS-specific neurofilament...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...